Could a single dose of pneurnococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination

被引：12

作者：

Barzilay, EJ

O'Brien, KL

Kwok, YS

Hoekstra, RM

Zell, ER

Reid, R

Santosham, M

Whitney, CG

Feikin, DR

机构：

[1] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Resp Dis Branch, Atlanta, GA 30333 USA

[2] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA

[3] Johns Hopkins Univ, Sch Publ Hlth, Ctr Amer Indian Hlth, Baltimore, MD USA

[4] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA

[5] Ctr Dis Control & Prevent, Biostat Informat Managment Branch, Atlanta, GA USA

来源：

VACCINE | 2006年 / 24卷 / 07期

关键词：

pneumococcal conjugate vaccine; Markov model; reduced dose vaccination model;

D O I：

10.1016/j.vaccine.2005.08.092

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Using incidence rates from CDC's Active Bacterial Core surveillance and immunogenicity data from the Navajo/Apache trial of pneumococcal conjugate vaccine (PCV), we used Markov modeling to predict the optimal age to give a single dose of PCV. Antibody concentration thresholds of 0.35 and 1.0 mcg/ml were considered protective. Our outcome was vaccine serotype-specific invasive pneumococcal disease (IPD) incidence at 24 months. The models predicted the optimal age to vaccinate is 5-7 months with vaccine-induced immunologic memory and 8-10 months without memory. IPD reduction ranged from 15 to 62%, depending on model parameters. A single PCV dose in infants could prevent substantial IPD. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：904 / 913

页数：10

共 44 条

[1] DECLINE OF CHILDHOOD HAEMOPHILUS-INFLUENZAE TYPE-B (HIB) DISEASE IN THE HIB VACCINE ERA [J].

ADAMS, WG ;

DEAVER, KA ;

COCHI, SL ;

PLIKAYTIS, BD ;

ZELL, ER ;

BROOME, CV ;

WENGER, JD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (02) :221-226

[2] Streptococcus pneumonia capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory [J].

Åhman, H ;

Käyhty, H ;

Lehtonen, H ;

Leroy, O ;

Froeschle, J ;

Eskola, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (03) :211-216

[3] Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants [J].

Ahman, H ;

Kayhty, H ;

Tamminen, P ;

Vuorela, A ;

Malinoski, F ;

Eskola, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (02) :134-139

[4] Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants [J].

Anderson, EL ;

Kennedy, DJ ;

Geldmacher, KM ;

Donnelly, J ;

Mendelman, PM .

JOURNAL OF PEDIATRICS, 1996, 128 (05) :649-653

[5]

[Anonymous], 2000, MMWR Recomm Rep, V49, P1

[6] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].

Black, S ;

Shinefield, H ;

Fireman, B ;

Lewis, E ;

Ray, P ;

Hansen, JR ;

Elvin, L ;

Ensor, KM ;

Hackell, J ;

Siber, G ;

Malinoski, F ;

Madore, D ;

Chang, I ;

Kohberger, R ;

Watson, W ;

Austrian, R ;

Edwards, K .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195

[7]

*CDCP, 2002, JAMA-J AM MED ASSOC, V287, P833

[8]

*CDCP, 2005, VACC CHILDR VACC PRI

[9] Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger [J].

Chippaux, JP ;

Garba, A ;

Ethevenaux, C ;

Campagne, G ;

de Chabalier, F ;

Djibo, S ;

Nicolas, P ;

Ali, H ;

Charrondière, M ;

Ryall, R ;

Bybel, M ;

Schuchat, A .

VACCINE, 2004, 22 (25-26) :3303-3311

[10] Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilus influenzae type b conjugate vaccine in United Kingdom infants [J].

Choo, S ;

Seymour, L ;

Morris, R ;

Quataert, S ;

Lockhart, S ;

Cartwright, K ;

Finn, A .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (09) :854-862

← 1 2 3 4 5 →